• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

胸腺癌中的C-KIT突变

C-KIT mutation in thymic carcinomas.

作者信息

Terzi Neslihan, Yilmaz Ismail, Batur Sebnem, Yegen Gulcin, Yol Cansu, Arikan Evsen, Oz Aysim

机构信息

Department of Pathology, University of Health Sciences, Sultan Abdulhamid Han Training and Research Hospital, Istanbul, Turkey.

Department of Pathology, Cerrahpasa University, Cerrahpasa Medical Faculty, Istanbul, Turkey.

出版信息

Pol J Pathol. 2020;71(2):120-126. doi: 10.5114/pjp.2020.97019.

DOI:10.5114/pjp.2020.97019
PMID:32729302
Abstract

Thymic epithelial tumours are rare malignancies of the anterior superior mediastinum. Several studies have analysed the presence of c-KIT mutations in thymic carcinoma. Immunohistochemical c-KIT expression and mutations in exons 8, 9, 11, 13, 14, 17, and 18 of the KIT gene and in the promoter region of the TERT gene (chr5, 1,295,228C>T/A and 1,295,250C>T) were analysed by PCR based direct sequencing using representative formalin-fixed paraffin-embedded tumour samples of 18 thymic carcinomas. Of 18 patients, 4 test samples were excluded from the study due to inadequate DNA quality. Of 14 patients with thymic carcinomas, KIT and TERT mutation was not detected in any samples. C-KIT expression was associated with nearly a worse overall survival (median time 24.160-49.840, log-rank, p = 0.05). We showed that squamous cell carcinomas led to worse survival than other subtypes. As expected, TNM stage II was significantly correlated with better OS (p = 0.015). Thymic carcinoma is characterised by a KIT-positive and CD5-positive staining pattern. We report a worse overall survival for patients with c-kit expressing tumours. These data suggest a negative prognostic role for c-kit expression especially within the first 5 years.

摘要

胸腺上皮肿瘤是前上纵隔罕见的恶性肿瘤。多项研究分析了胸腺癌中c-KIT突变的存在情况。使用18例胸腺癌的代表性福尔马林固定石蜡包埋肿瘤样本,通过基于PCR的直接测序分析了KIT基因外显子8、9、11、13、14、17和18以及TERT基因启动子区域(chr5,1,295,228C>T/A和1,295,250C>T)的免疫组化c-KIT表达和突变情况。18例患者中,4个检测样本因DNA质量不足被排除在研究之外。14例胸腺癌患者的样本中均未检测到KIT和TERT突变。c-KIT表达与总体生存率较差相关(中位时间24.160 - 49.840,对数秩检验,p = 0.05)。我们发现鳞状细胞癌的生存率低于其他亚型。正如预期的那样,TNM II期与更好的总生存期显著相关(p =

相似文献

1
C-KIT mutation in thymic carcinomas.胸腺癌中的C-KIT突变
Pol J Pathol. 2020;71(2):120-126. doi: 10.5114/pjp.2020.97019.
2
Absence of gene mutations in KIT-positive thymic epithelial tumors.KIT阳性胸腺上皮肿瘤中无基因突变。
Lung Cancer. 2008 Dec;62(3):321-5. doi: 10.1016/j.lungcan.2008.03.035. Epub 2008 May 19.
3
Expression and mutational status of c-kit in thymic epithelial tumors.c-kit 在胸腺瘤中的表达与突变状态。
J Thorac Oncol. 2010 Sep;5(9):1447-53. doi: 10.1097/JTO.0b013e3181e96e30.
4
Mutational status of EGFR and KIT in thymoma and thymic carcinoma.胸腺瘤和胸腺癌中表皮生长因子受体(EGFR)和原癌基因c-KIT的突变状态
Lung Cancer. 2008 Dec;62(3):316-20. doi: 10.1016/j.lungcan.2008.03.013. Epub 2008 Apr 29.
5
Activating c-KIT mutations in a subset of thymic carcinoma and response to different c-KIT inhibitors.激活一组胸腺癌中的 c-KIT 突变和对不同 c-KIT 抑制剂的反应。
Ann Oncol. 2012 Sep;23(9):2409-2414. doi: 10.1093/annonc/mdr626. Epub 2012 Feb 21.
6
Immunohistochemical KIT (CD117) expression in thymic epithelial tumors.免疫组化检测KIT(CD117)在胸腺上皮肿瘤中的表达
Chest. 2005 Jul;128(1):140-4. doi: 10.1378/chest.128.1.140.
7
Analysis of a panel of druggable gene mutations and of ALK and PD-L1 expression in a series of thymic epithelial tumors (TETs).一组可用药基因突变及 ALK 和 PD-L1 表达在胸腺瘤系列中的分析。
Lung Cancer. 2017 Feb;104:24-30. doi: 10.1016/j.lungcan.2016.12.005. Epub 2016 Dec 14.
8
Comprehensive genomic analysis reveals clinically relevant molecular distinctions between thymic carcinomas and thymomas.全面的基因组分析揭示了胸腺癌和胸腺瘤之间具有临床意义的分子差异。
Clin Cancer Res. 2009 Nov 15;15(22):6790-9. doi: 10.1158/1078-0432.CCR-09-0644. Epub 2009 Oct 27.
9
KIT (CD117) is frequently overexpressed in thymic carcinomas but is absent in thymomas.KIT(CD117)在胸腺癌中常过度表达,但在胸腺瘤中不存在。
J Pathol. 2004 Mar;202(3):375-81. doi: 10.1002/path.1514.
10
Identification of Recurrent TERT Promoter Mutations in Intrathyroid Thymic Carcinomas.甲状腺内胸腺癌中 TERT 启动子突变的鉴定。
Endocr Pathol. 2020 Sep;31(3):274-282. doi: 10.1007/s12022-020-09635-0.

引用本文的文献

1
CD5 Immunoreactivity Is Associated With Longer Overall Survival in Thymic Carcinoma: A Brief Report.CD5免疫反应性与胸腺癌患者更长的总生存期相关:一篇简短报告
JTO Clin Res Rep. 2025 Feb 11;6(5):100803. doi: 10.1016/j.jtocrr.2025.100803. eCollection 2025 May.
2
Insights into molecular aspects and targeted therapy of thymic carcinoma: a narrative review.胸腺癌的分子机制及靶向治疗研究进展:一篇综述
Mediastinum. 2024 Mar 21;8:36. doi: 10.21037/med-23-48. eCollection 2024.
3
Molecular and Functional Key Features and Oncogenic Drivers in Thymic Carcinomas.
胸腺癌的分子与功能关键特征及致癌驱动因素
Cancers (Basel). 2023 Dec 29;16(1):166. doi: 10.3390/cancers16010166.
4
Clinical Significance of Tumor Markers for Advanced Thymic Carcinoma: A Retrospective Analysis from the NEJ023 Study.晚期胸腺癌肿瘤标志物的临床意义:来自NEJ023研究的回顾性分析
Cancers (Basel). 2022 Jan 11;14(2):331. doi: 10.3390/cancers14020331.
5
Mutational landscape of thymic epithelial tumors in a Chinese population: insights into potential clinical implications.中国人群胸腺上皮肿瘤的突变图谱:对潜在临床意义的见解。
Gland Surg. 2021 Apr;10(4):1410-1417. doi: 10.21037/gs-21-157.